Role of GHRH Antagonist MIA-602 in AML Treatment | Oncotarget [Video]

Oncotarget #published this #trending research #paper on April 8, 2024 in Volume 15, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia” by researchers from the Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL; Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton; Veterans Affairs Medical Center, Miami, FL. @UMiamiMedicine @FAUMedicalSchool
#cancer #leukemia #aml #research #researchpaper #oncology #openaccess #openscience #peerreview #journal #publication #publishing #meded

DOI – https://doi.org/10.18632/oncotarget.28579

Correspondence to – Simonetta I. Gaumond – [email protected]

Abstract

Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. This investigation examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorubicin-resistant AML cell lines, KG-1A, U-937, and K-562. The in vitro results revealed a significant reduction in cell viability for all treated wild-type cells. Doxorubicin-resistant clones were similarly susceptible to MIA-602 as the wild-type counterpart. Our in vivo experiment of xenografted nude mice with Doxorubicin-resistant K-562 revealed a reduction in tumor volume with MIA-602 treatment compared to control. Our study demonstrates that these three AML cell lines, and their Doxorubicin-resistant clones, are susceptible to GHRH antagonist MIA-602.

Sign up for free Altmetric alerts about this article – https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28579

Subscribe for free publication alerts from Oncotarget – https://www.oncotarget.com/subscribe/

Keywords – cancer, leukemia, AML, resistance, growth hormone-releasing hormone, MIA-602

About Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook – https://www.facebook.com/Oncotarget/
X – https://twitter.com/oncotarget
Instagram – https://www.instagram.com/oncotargetjrnl/
YouTube – https://www.youtube.com/@OncotargetJournal
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/
Spotify – https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

Media Contact
[email protected]
18009220957